We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell t... Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for treating Duchenne muscular dystrophy (DMD). Capricor is also developing its exosome technology as a next-generation therapeutic platform. Capricor's proprietary StealthX¿ exosome platform has potential for a broad range of new therapeutic applications in the field of vaccinology as well as targeted oligonucleotide, protein and small molecule therapeutics to treat or prevent a variety of diseases. Show more
-Company Aligned with FDA on Demonstration of Non-Clinical Comparability; Allowing for Immediate Use of San Diego Manufacturing Facility- -FDA Feedback Supports Requests for a Pre-BLA Meeting and...
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and...
-Enrollment Complete in Cohort A of Phase 3, Pivotal, HOPE-3 Trial of CAP-1002 inΒ Duchenne Muscular Dystrophy; Announced Successful Interim Futility Analysis; On Track to Report Top-Line Data in...
SAN DIEGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- β Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and...
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and...
-Cohort B of HOPE-3, Phase 3 Clinical Trial Expected to Complete Enrollment in Second Quarter 2024- SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a...
-Project NextGen Collaboration will Support Capricorβs StealthXβ’ Exosome Platform and Provide Non-Dilutive Support for Advancement into the Clinic- SAN DIEGO, Jan. 24, 2024 (GLOBE NEWSWIRE...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.57 | 11.4 | 5 | 5.6463 | 4.7 | 499434 | 4.99638542 | CS |
4 | -1.22 | -17.9675994109 | 6.79 | 7.28 | 4.685 | 369047 | 5.69507252 | CS |
12 | 1.53 | 37.8712871287 | 4.04 | 7.28 | 3.56 | 323114 | 5.6010226 | CS |
26 | 2.81 | 101.811594203 | 2.76 | 7.28 | 2.68 | 276492 | 4.84666158 | CS |
52 | 1.64 | 41.7302798982 | 3.93 | 8.2212 | 2.68 | 217368 | 4.74126827 | CS |
156 | 1.65 | 42.0918367347 | 3.92 | 8.2212 | 2.56 | 266483 | 4.56819967 | CS |
260 | 5.075 | 1025.25252525 | 0.495 | 12.32 | 0.2526 | 757173 | 5.92123204 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions